Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0023473 (
chronic myeloid leukemia
)
18,916
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The production of leukotrienes (LT) in peripheral blood leukocyte preparations from 9 patients with
chronic myelogenous leukemia
(
CML
) and 9 healthy controls was studied. Leukotriene generation was stimulated by the calcium ionophore A 23187 (1 mumol). Lipoxygenase products were separated and identified using a high performance liquid chromatography (HPLC) technique and computerized spectrophotometry. Leukotriene C4 (LTC4) was formed in significantly larger amounts by cells from the
CML
patients than cells from the controls; 14.4 +/- 4.3 pmol per 10(6) nucleated cells (mean +/- SE) and 4.0 +/- 1.2 pmol respectively (p less than 0.05). Seven of the 9 patients but none of the controls synthesized equal or higher amounts of LTC4 than LTB4. A highly significant difference in mean values of LTC4/(LTB4 + 20-OH-LTB4) ratios was observed;
CML
0.69 +/- 0.08 versus controls 0.12 +/- 0.02, p less than 0.001. These findings suggest an increased
LTC4 synthase
activity in
CML
cells. In earlier studies we have found a decreased 12-lipoxygenase activity in
CML
bone marrow cells.
...
PMID:Increased leukotriene C4 production in chronic myelogenous leukemia. 285 46
Leukotrienes (LT) are inflammatory mediators which can also exert regulatory effects on human myelopoiesis. We have studied the LT-producing capacity of freshly isolated leucocyte suspensions (containing blast cells in variable proportions) from 41 patients with acute myeloid leukaemia (AML) or
chronic myeloid leukaemia
(
CML
) in blast crisis (CMLbc) at diagnosis or relapse/resistant disease. Leucocyte suspensions from 19/29 AML patients (66%), and 2/12 CMLbc patients (17%; P = 0.012) demonstrated deficient capacity to synthesize LT from endogenous substrate after ionophore A23187 stimulation. Thus, these cells produced < 8 pmol LTB4+LTC4/10(6) cells (< 20% of mean LT formation in leucocyte suspensions from 18 healthy subjects). Addition of exogenous arachidonic acid did not normalize the LT synthesis in poor-producing cell suspensions. Purified, morphologically mature granulocytes from two AML patients also failed to produce normal amounts of LT. In leucocyte suspensions from the remaining 20 AML/CMLbc patients A23187 provoked LT biosynthesis, with markedly increased production of LTC4, but decreased LTB4 formation. Furthermore, elevated conversion of exogenous LTA4 to LTC4 was noted in the patient samples, independent of their capacity to produce LT after A23187 stimulation. The percentage of blast cells in patient white blood cell differential counts correlated inversely with ionophore-induced LT synthesis, but positively with the conversion of exogenous LTA4 to LTC4. The results suggest elevated
LTC4 synthase
activity and suppressed 5-lipoxygenase activity as novel enzymatic features of myeloid leukaemia patients with immature phenotype.
...
PMID:Novel enzymatic abnormalities in AML and CML in blast crisis: elevated leucocyte leukotriene C4 synthase activity paralleled by deficient leukotriene biosynthesis from endogenous substrate. 967 47
Elevated leukotriene (LT)C(4) synthase activity was observed in peripheral blood granulocyte suspensions from patients with
chronic myeloid leukemia
(
CML
). Magnetic cell sorting (MACS) with CD16 monoclonal antibodies (mAbs), which were used to fractionate granulocytes from
CML
patients and healthy individuals, yielded highly purified suspensions of CD16(+) neutrophils. The purity of these cell fractions was verified by extensive morphologic examination. Reverse transcriptase-polymerase chain reaction (RT-PCR) analyses, demonstrating the absence of interleukin-4 messenger RNA (IL-4 mRNA), further confirmed the negligible contamination of eosinophils in these fractions. Notably, purified
CML
CD16(+) neutrophils from all tested patients transformed exogenous LTA(4) to LTC(4). These cells also produced LTC(4 )after activation with ionophore A23187 or the chemotactic peptide fMet-LeuPhe (N-formylmethionyl-leucyl-phenylalanine). Subcellular fractionation revealed that the enzyme activity was exclusively distributed to the microsomal fraction. Expression of
LTC(4) synthase
mRNA in
CML
CD16(+) neutrophils was confirmed by RT-PCR. Furthermore, Western blot analyses consistently demonstrated expression of
LTC(4) synthase
at the protein level in
CML
CD16(+) neutrophils, whereas expression of microsomal glutathione S-transferase 2 occurred occasionally. Expectedly,
LTC(4) synthase
activity or expression of the protein could not be demonstrated in CD16(+) neutrophil suspensions from any of the healthy individuals. Instead, these cells, as well as
CML
CD16(+) neutrophils, transformed LTA(4) to LTB(4). The results indicate that aberrant expression of
LTC(4) synthase
is a regular feature of morphologically mature
CML
CD16(+) neutrophils. This abnormality, possibly associated with malignant transformation, can lead to increased LTC(4) synthesis in vivo. Such overproduction may be of pathophysiological relevance because LTC(4 )has been demonstrated to stimulate proliferation of human bone marrow-derived myeloid progenitor cells. (Blood. 2000;95:1456-1464)
...
PMID:Aberrant expression of active leukotriene C(4) synthase in CD16(+) neutrophils from patients with chronic myeloid leukemia. 1066 25
Neutrophils from patients with
chronic myeloid leukaemia
(
CML
) have an aberrant expression of leukotriene (LT)C4 synthase. In order to learn more about the regulation of this abnormality,
LTC4 synthase
mRNA expression was determined by reverse transcription polymerase chain reaction. A digoxigenin (DIG)-labelled
LTC4 synthase
RNA was synthesized and incubated in cytosolic extracts from
CML
neutrophils, normal neutrophils and eosinophils.
LTC4 synthase
mRNA was detected in total but not cytoplasmic RNA from normal neutrophils. In contrast,
LTC4 synthase
mRNA was found in the cytoplasm of
CML
neutrophils and in normal eosinophils, which also express the enzyme. The DIG-labelled
LTC4 synthase
RNA was, as opposed to normal neutrophils, degraded in cytosolic extracts from
CML
neutrophils. The degradation was time dependent and cell concentration dependent. Degradation was also seen in eosinophils, indicating that degradation of
LTC4 synthase
RNA was correlated to the expression of the protein. This study showed that the difference in expression of
LTC4 synthase
in normal and
CML
neutrophils was not because of a total lack of
LTC4 synthase
mRNA in normal neutrophils. However normal neutrophils lack, in contrast to
CML
neutrophils,
LTC4 synthase
mRNA in the cytoplasm. This discrepancy is not caused by a stabilized
LTC4 synthase
RNA in the cytosol of
CML
neutrophils. Instead an abnormal degradation of
LTC4 synthase
RNA was found in the cytosol of
CML
neutrophils.
...
PMID:Abnormal LTC4 synthase RNA degradation in neutrophils from CML patients. 1500 61